TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: AZD9668 active treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: AZD9668 placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): AZD9668 active treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AZD9668 placebo treatment
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)
C: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline 6% - | Intervention Type: DRUG; Name: Hypertonic saline 6% -; Assigned to Arm(s): 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Brief Summary: The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Options:
A: Arm Label: Ciprofloxacin dispersion for inhalation; Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin dispersion for inhalation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin dispersion for inhalation; Assigned to Arm(s): Ciprofloxacin dispersion for inhalation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: Ciprofloxacin dispersion for inhalation; Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin dispersion for inhalation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin dispersion for inhalation; Assigned to Arm(s): Ciprofloxacin dispersion for inhalation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Experimental Medicine, Randomized, Double-Blind Study Assessing Neuropsychiatric Symptoms In Quitting Smokers Treated With Varenicline Tartrate Or Placebo
Brief Summary: Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Experimental Medicine, Randomized, Double-Blind Study Assessing Neuropsychiatric Symptoms In Quitting Smokers Treated With Varenicline Tartrate Or Placebo
Brief Summary: Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of Integrating IC Technology With the WatchWT Comprehensive Weight Reduction Program.
Brief Summary: The purpose of this study is to evaluate the feasibility of using indirect calorimetry (IC) within a comprehensive weight reduction program. Will individuals that receive a personalized nutrition program, at baseline, from IC technology respond better to treatment compared to individuals receiving IC technology at three months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Face-to-face maintenance program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet maintenance program; Assigned to Arm(s): N/A
C: Arm Label: Face-to-face counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face counseling | Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling | Arm Label: Mail contact; Type: ACTIVE_COMPARATOR; Interventions: Other: Mail contact | Intervention Type: BEHAVIORAL; Name: Face-to-face counseling; Assigned to Arm(s): Face-to-face counseling | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Telephone Counseling | Intervention Type: OTHER; Name: Mail contact; Assigned to Arm(s): Mail contact
D: Arm Label: E1; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized IC treatment | Intervention Type: BEHAVIORAL; Name: Individualized IC treatment; Assigned to Arm(s): A1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): E1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project 2 (Mayo): Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients
Brief Summary: Specific aim: To test whether transfusion of leukoreduced red cells of lesser storage time (versus conventional storage time) reduces mild alterations in pulmonary function and immune activation in critically ill patients with mechanically ventilated lungs.

We propose to perform a prospective, randomized, double-blind clinical trial in critically ill patients whose lungs are mechanically ventilated, and who have orders to receive transfusion of at least one unit of packed red cells, comparing pulmonary function between patients randomly allocated to receive a unit of red cells stored for 5 days or less, with similar patients randomly allocated to receive a unit of red cells stored conventionally (median 21 days). We will test the hypothesis that transfusion of red cells of lesser storage age, (5 days or less) will produce the less changes of pulmonary function and immune activation than will transfusion of red cells of conventional storage age (median 21 days).


Options:
A: Arm Label: Short storage; Type: EXPERIMENTAL; Interventions: Biological: Blood transfusion | Arm Label: Long storage arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Long storage arm, Short storage
B: Arm Label: Prolonged RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prolonged RBC storage | Arm Label: Short RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Short RBC storage | Intervention Type: BIOLOGICAL; Name: Prolonged RBC storage; Assigned to Arm(s): Prolonged RBC storage | Intervention Type: BIOLOGICAL; Name: Short RBC storage; Assigned to Arm(s): Short RBC storage
C: Arm Label: Fresh not-leukocyte-reduced RBCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: Fresh RBCs leukocyte-reduced; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: RBCs with storage longer than 15 days; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Fresh RBCs leukocyte-reduced, Fresh not-leukocyte-reduced RBCs, RBCs with storage longer than 15 days
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2

Answer: D